AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6123287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (30 mg bid)
Number of subjects: 56
Study 6123287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31382998 — intervention group
Group type: COMPARATOR
Intervention: Computer-based cognitive rehabilitation (CCR) group: RehaCom cognitive rehabilitation once (30 min) a day, 3 days per week for 8 weeks.
Number of subjects: 36
Study 31382998 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with computer-based cognitive rehabilitation (EA-CCR) group: EA at Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), and Shenting (GV24) plus RehaCom cognitive rehabilitation once (30 min each) a day, 3 days per week for 8 weeks.
Number of subjects: 36
Study 31382998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CCR and EA-CCR)
Number of subjects: 36
Study 30374316 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARE (Spouses coping with the Head And neck Radiation Experience)
Number of subjects: 60
Study 30374316 — intervention group
Group type: COMPARATOR
Intervention: Usual Medical Care (UMC)
Number of subjects: 60
Study 26923888 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage group (received a drain at the end of operation)
Number of subjects: 92
Study 26923888 — intervention group
Group type: COMPARATOR
Intervention: Control group (didn't receive a drain)
Number of subjects: 92
Study 26923888 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage group
Number of subjects: 92
Study 25631731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 60
Study 25631731 — intervention group
Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 60
Study 22507228 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 16
Study 22507228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21287904 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent peer review visits
Number of subjects: 727
Study 21287904 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 727
Study 17613581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise group
Number of subjects: 75
Study 17613581 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise group
Number of subjects: 75
Study 16247343 — intervention group
Group type: EXPERIMENTAL
Intervention: Twist drill craniostomy (TDC) with closed-system drainage and suction reservoir
Number of subjects: 47
Study 16247343 — intervention group
Group type: COMPARATOR
Intervention: Burr hole craniotomy (BHC) with subdural irrigation and closed drainage
Number of subjects: 47
Study 12759845 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 12759845 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 0
Study 12759845 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 0
Study 12759845 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis treatments
Number of subjects: 0
Study 12759845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9527146 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g/day piracetam
Number of subjects: 20
Study 9527146 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.8 g/day piracetam
Number of subjects: 20
Study 9527146 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.6 g/day piracetam
Number of subjects: 20
Study 9527146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7605861 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of famotidine 40 mg/day
Number of subjects: 12
Study 7605861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrojet device delivering famotidine
Number of subjects: 12
Study 2357194 — intervention group
Group type: EXPERIMENTAL
Intervention: MR Imaging using a 0.3 Tesla low field strength scanner
Number of subjects: 50
Study 7246468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic sensory imagery conditioning program (three-week duration, daily sessions with three conditioning images and self-hypnotic practice)
Number of subjects: 60
Study 7246468 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment control condition
Number of subjects: 60
Study 31246097 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella microaxillar mechanical support
Number of subjects: 15
Study 31436643 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐SLET
Number of subjects: 92
Study 31436643 — intervention group
Group type: COMPARATOR
Intervention: CAG
Number of subjects: 92
Study 27856088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1445
Study 27856088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1445
Study 26491667 — intervention group
Group type: EXPERIMENTAL
Intervention: Print and post communications
Number of subjects: 221
Study 26491667 — intervention group
Group type: EXPERIMENTAL
Intervention: Email communications
Number of subjects: 221
Study 26491667 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone communications
Number of subjects: 221
Study 26491667 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 221
Study 26491667 — intervention group
Group type: EXPERIMENTAL
Intervention: Private Internet‐based social network messages
Number of subjects: 221
Study 24450252 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (TAM) 0.4 mg daily
Number of subjects: 265
Study 24450252 — intervention group
Group type: COMPARATOR
Intervention: Serenoa repens (SR) 320 mg daily
Number of subjects: 265
Study 24450252 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (TAM) 0.4 mg daily + Serenoa repens (SR) 320 mg daily
Number of subjects: 265
Study 21298443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia subjects (younger and middle-aged)
Number of subjects: 60
Study 21298443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia subjects (middle-aged)
Number of subjects: 60
Study 21298443 — intervention group
Group type: EXPERIMENTAL
Intervention: Older fibromyalgia subjects
Number of subjects: 60
Study 21298443 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study 19807860 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being therapy
Number of subjects: 0
Study 21404452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-volume infusion of hydroxyethyl starch (HES) at a dose of 15 ml/kg/day
Number of subjects: 0
Study 16188857 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based counselling by breastfeeding counsellors (n=68)
Number of subjects: 204
Study 16188857 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based counselling by general childcare counsellors (n=67)
Number of subjects: 204
Study 16188857 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=69)
Number of subjects: 204
Study 16188857 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 204
Study 16188857 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding counselled group
Number of subjects: 204
Study 16188857 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants exclusively breastfed for 6 months
Number of subjects: 204
Study 12162272 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm dosing of acenocoumarol
Number of subjects: 103
Study 12162272 — intervention group
Group type: COMPARATOR
Intervention: Routine dosing of acenocoumarol
Number of subjects: 103
Study 10829375 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-link instruction
Number of subjects: 4
Study 10829375 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone instruction
Number of subjects: 4
Study 10829375 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous CPR training
Number of subjects: 4
Study 10829375 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observer instruction
Number of subjects: 4
Study 10829375 — intervention group
Group type: COMPARATOR
Intervention: No instruction
Number of subjects: 4
Study 8519713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with epinephrine concentrations of 0, 1:50,000, 1:200,000, 1:800,000, and 1:3,200,000
Number of subjects: 6
Study 8519713 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with epinephrine concentrations of 0, 1:50,000, 1:200,000, 1:800,000, and 1:3,200,000
Number of subjects: 6
Study 8519713 — intervention group
Group type: COMPARATOR
Intervention: Plain local anesthesia (without epinephrine)
Number of subjects: 6
Study 8519713 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-induced vasoconstriction
Number of subjects: 6
Study 2363117 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. low-dose aspirin
Number of subjects: 21
Study 2363117 — intervention group
Group type: COMPARATOR
Intervention: i.v. isosorbide dinitrate and oral diltiazem
Number of subjects: 21
Study 507079 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-micrometers membrane filter
Number of subjects: 150
Study 507079 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45-micrometers membrane filter
Number of subjects: 150
Study 507079 — intervention group
Group type: COMPARATOR
Intervention: Control (no filter)
Number of subjects: 150
Study 12587621 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg per day of intravenous rGCSF once daily for 3 days
Number of subjects: 40
Study 12587621 — intervention group
Group type: COMPARATOR
Intervention: Physiological serum (control group)
Number of subjects: 40
Study 29775141 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group reminiscence therapy for 8 weeks
Number of subjects: 0
Study 29775141 — intervention group
Group type: COMPARATOR
Intervention: Daily activities (Control)
Number of subjects: 0
Study 26860786 — intervention group
Group type: EXPERIMENTAL
Intervention: Management training (90-min training session)
Number of subjects: 434
Study 26860786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no management training)
Number of subjects: 434
Study 24022378 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis
Number of subjects: 79
Study 24022378 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 79
Study 23478699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower protein diet (< 22% daily energy intake) + Resistance Training (RT)
Number of subjects: 25
Study 23478699 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (> 22% daily energy intake) + Resistance Training (RT)
Number of subjects: 25
Study 23478699 — intervention group
Group type: COMPARATOR
Intervention: Lower protein diet (< 22% daily energy intake) + Habitual activity (Control)
Number of subjects: 25
Study 23478699 — intervention group
Group type: COMPARATOR
Intervention: Higher protein diet (> 22% daily energy intake) + Habitual activity (Control)
Number of subjects: 25
Study 23478699 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 25
Study 23478699 — intervention group
Group type: COMPARATOR
Intervention: Habitual activity (Control)
Number of subjects: 25
Study 20034682 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected activated macrophage suspension (AMS)
Number of subjects: 100
Study 20034682 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 100
Study 18929746 — intervention group
Group type: EXPERIMENTAL
Intervention: POR group (specialized rehabilitation sessions repeated after 90 days)
Number of subjects: 149
Study 18929746 — intervention group
Group type: COMPARATOR
Intervention: PO group (limited rehabilitation)
Number of subjects: 149
Study 15944095 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD‐CLS pacing
Number of subjects: 17
Study 15944095 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 17
Study 12011547 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist-300 with VM for 5 s starting 5 s after injection
Number of subjects: 64
Study 12011547 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist-200 with VM for 5 s starting 5 s after injection
Number of subjects: 64
Study 12011547 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist-300 with VM for 5 s starting with the beginning of injection
Number of subjects: 64
Study 12011547 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist-300 with VM for 5 s starting 10 s after injection
Number of subjects: 64
Study 12011547 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist-200 with VM for 5 s starting with the beginning of injection
Number of subjects: 64
Study 12011547 — intervention group
Group type: EXPERIMENTAL
Intervention: No VM
Number of subjects: 64
Study 10424515 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG) induction therapy (1.5 mg/kg/d for 3 days)
Number of subjects: 44
Study 10424515 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression alone (no induction therapy)
Number of subjects: 44
Study 10424515 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG) induction therapy
Number of subjects: 44
Study 7772355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic laryngoscopy with atlanto‐occipital joint in the extended position
Number of subjects: 20
Study 7772355 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic laryngoscopy with atlanto‐occipital joint in the neutral position
Number of subjects: 20
Study 2181621 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen tablets
Number of subjects: 12
Study 2181621 — intervention group
Group type: COMPARATOR
Intervention: Plain naproxen tablets
Number of subjects: 12
Study 159848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nursery care
Number of subjects: 143
Study 159848 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 143
Study 159848 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 143
Study 31627773 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial agents (specific agents not detailed)
Number of subjects: 21
Study 31627773 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study 29307310 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee bean extract (GCE) 400 mg twice per day for 8 weeks
Number of subjects: 0
Study 27175447 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum L-137 (HK L-137) 10 mg daily for 12 weeks
Number of subjects: 39
Study 27175447 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule daily for 12 weeks
Number of subjects: 39
Study 25225951 — intervention group
Group type: EXPERIMENTAL
Intervention: EEN combined with rhubarb
Number of subjects: 126
Study 21264685 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cheese containing Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM
Number of subjects: 31
Study 21264685 — intervention group
Group type: COMPARATOR
Intervention: Plain cheese without probiotics
Number of subjects: 31
Study 20380764 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillotomy
Number of subjects: 26
Study 20380764 — intervention group
Group type: COMPARATOR
Intervention: Laser tonsillotomy
Number of subjects: 26
Study 20380764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 26
Study 17395053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Restriction (FR)
Number of subjects: 67
Study 17395053 — intervention group
Group type: COMPARATOR
Intervention: Free Fluid (FF)
Number of subjects: 67
Study 15629834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 57
Study 15629834 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival saline (control)
Number of subjects: 57
Study 11758798 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a dog during mental stress
Number of subjects: 72
Study 11758798 — intervention group
Group type: COMPARATOR
Intervention: No dog present during mental stress
Number of subjects: 72
Study 9504571 — intervention group
Group type: COMPARATOR
Intervention: Control (35% of energy as fat)
Number of subjects: 37
Study 9504571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat 1 (15% of energy as fat)
Number of subjects: 37
Study 9504571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat 2 (50% of fat in the form of fish oil)
Number of subjects: 37
Study 9504571 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 37
Study 8069055 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative method (VDSG)
Number of subjects: 66
Study 8069055 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative method (VDIM)
Number of subjects: 66
Study 8069055 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in spinal deformation (SDIM)
Number of subjects: 66
Study 8069055 — intervention group
Group type: EXPERIMENTAL
Intervention: VDIM for detecting vertebral fracture progression
Number of subjects: 66
Study 8069055 — intervention group
Group type: EXPERIMENTAL
Intervention: VDSG for diagnosing vertebra fractures
Number of subjects: 66
Study 8069055 — intervention group
Group type: EXPERIMENTAL
Intervention: VDIM for diagnosing vertebra fractures
Number of subjects: 66
Study 8069055 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline spinal deformation (SDIM and SDIG)
Number of subjects: 66
Study 2923770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation during regional conduction block without oxygen; 4 patients
Number of subjects: 10
Study 2923770 — intervention group
Group type: COMPARATOR
Intervention: Sedation during regional conduction block with oxygen (2 litre min‐1 via nasal catheter); 6 patients
Number of subjects: 10
Study 30917927 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 85-8501 (1 mg once daily for 28 days)
Number of subjects: 94
Study 30917927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 26992377 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV
Number of subjects: 58
Study 26992377 — intervention group
Group type: COMPARATOR
Intervention: VCV
Number of subjects: 58
Study 25933488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (7000 μg retinol equivalents)
Number of subjects: 290
Study 25933488 — intervention group
Group type: COMPARATOR
Intervention: β-carotene supplementation
Number of subjects: 290
Study 25933488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 25933488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 290
Study 22651957 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.2mg)
Number of subjects: 0
Study 22651957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22651957 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 22049673 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP intervention
Number of subjects: 348
Study 22049673 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 348
Study 19928386 — intervention group
Group type: EXPERIMENTAL
Intervention: TIB restriction (90 minutes less than recorded during baseline)
Number of subjects: 42
Study 19928386 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (fixed sleep schedule consistent with average baseline, no TIB restriction)
Number of subjects: 42
Study 16355285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (2 mg/day)
Number of subjects: 87
Study 16355285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 15085035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% with sodium bicarbonate
Number of subjects: 47
Study 15085035 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% with benzyl alcohol
Number of subjects: 47
Study 11125713 — intervention group
Group type: COMPARATOR
Intervention: 0 mg glycyrrhizic acid/kg body weight
Number of subjects: 39
Study 11125713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glycyrrhizic acid/kg body weight
Number of subjects: 39
Study 11125713 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg glycyrrhizic acid/kg body weight
Number of subjects: 39
Study 11125713 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg glycyrrhizic acid/kg body weight
Number of subjects: 39
Study 9042977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 500 mg b.d.
Number of subjects: 236
Study 9042977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg q.d.s.
Number of subjects: 236
Study 7837158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment
Number of subjects: 167
Study 7837158 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 167
Study 3062082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 250 mg/day
Number of subjects: 30
Study 3062082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 500 mg/day
Number of subjects: 30
Study 3062082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 750 mg/day
Number of subjects: 30
Study 31802732 — intervention group
Group type: EXPERIMENTAL
Intervention: ePOCT (weight‐for‐age and mid‐upper arm circumference)
Number of subjects: 106
Study 31802732 — intervention group
Group type: COMPARATOR
Intervention: ALMANACH (clinical signs of edema of both feet and visible severe wasting)
Number of subjects: 106
Study 30316696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen (1 mg kg–1 IV; administered every 8 hours)
Number of subjects: 38
Study 30316696 — intervention group
Group type: COMPARATOR
Intervention: Methadone (0.2 mg kg–1 IV; administered every 4 hours)
Number of subjects: 38
Study 30316696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 38
Study 26080652 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 2.5 mg
Number of subjects: 75
Study 26080652 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 75
Study 26080652 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 75